by Jordana Choucair | Feb 3, 2022 | Payers
The CMS proposed a 7.98 percent increase to Medicare Advantage (MA) payment next year, nearly double the pay increase that plans saw in 2022. CMS also said MA groups could be judged in the future on their value-based care arrangements with providers, and asked for...
by Jordana Choucair | Feb 3, 2022 | Payers
The U.S. Army will immediately begin discharging service members who have refused to get the COVID-19 vaccine. The development follows similar moves from other military branches and puts more than 3,300 soldiers at risk of being kicked out. About 97 percent of all...
by Jordana Choucair | Feb 3, 2022 | Opioid/Substance Use Disorders
A study published in the Lancet found that the opioid epidemic could claim another 1.2 million lives in North America over the next seven years. The researchers warned that the epidemic may widen globally without stricter regulation to stop companies from exporting...
by Jordana Choucair | Feb 3, 2022 | Mental Health
Eleven groups wrote a letter to HHS voicing concerns with the price transparency provision of the law to ban surprise billing. The provision requires most licensed medical practitioners to give patients detailed upfront cost estimates, including a diagnosis, and...
by Jordana Choucair | Feb 3, 2022 | M&A
Amedisys announced it signed a definitive agreement to buy Evolution Health from Envision Healthcare. The deal, which should close by June of this year, will give Amedisys access to the more than 3,300 home health patients Evolution Health serves daily. “Amedisys will...
by Jordana Choucair | Feb 3, 2022 | Life Sciences
Merck & Co. said it expects its sales to surge by up to 18 percent in 2022 compared with last year, primarily driven by demand for the COVID-19 antiviral pill molnupiravir. Merck said sales of the drug, which it developed with Ridgeback Biotherapeutics LP, reached...
Recent Comments